A perioperative study confirmed brain penetrance and robust biomarker suppression in patients with low-grade glioma with an IDH1 mutation.
Using RNA sequencing for individual pediatric cancer cases could more effectively target gene expression in tumors.
Researchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.
There could be a new way to diagnose brain tumors earlier.
Investigators assessed effects of TIB on cell number, migration, invasion, estrogen, and progesterone receptor activity and content.
A new study offers hope in predicting glioblastoma responses to chemotherapy, radiation, and combination therapy.
Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma
Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.
Cancer Network spoke with Dr. Shulin Li about his team’s research on the role of the FGL2 protein in glioblastoma immune evasion and tumor progression.
This review focuses on clinical developments and management of newly diagnosed glioblastoma, and includes a discussion about the incorporation of molecular features into the classification of this disease.
Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.